Table 2. Antibody persistence as defined by HI antibody titer at 6/15/22-months following the first vaccination with clade 1 A/Vietnam/1194/2004/NIBERG-14.
| Age Groups | 160 years | > 60 years | ||||||
|---|---|---|---|---|---|---|---|---|
| Primary vaccination | 7.5 μg | 30 μg + Adjuvant | 7.5 μg | 30 μg + Adjuvant | ||||
| Time (months) since vaccination | 6 (n = 146) | 6 (n = 146) | 15 (n = 98) | 22 (n = 95) | 6 (n = 146) | 6 (n = 148) | 15 (n = 101) | 22 (n = 94) |
| % subjects with GMT ≥ 32 (95% CI) | 6.2 (2.9; 11.4) | 6.2 (2.9; 11.4) | 3.1 (0.6; 8.7) | 1.1 (0.0; 5.7) | 14.4 (9.1; 21.1) | 18.9 (13.0; 26.2) | 12.9 (7.0; 21) | 11.7 (6.0; 20) |
| GMT (95% CI) | 5.43 (4.85; 6.08) | 5.99 (5.33; 6.73) | 4.6 (4.20; 5.06) | 4.33 (4.03; 4.66) | 7.63 (6.41; 9.08) | 9.42 (7.78; 11.42) | 6.8 (5.55; 8.30) | 6.37 (5.22; 7.76) |
GMT: Geometric mean titer n = number of participants